




RealRate

PHARMACEUTICAL 2012

United Therapeutics Corp
Rank 64 of 196



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of United Therapeutics Corp are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of United Therapeutics Corp compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 60% points. The greatest weakness of United Therapeutics Corp is the variable Other Liabilities, reducing the Economic Capital Ratio by 25% points.

The company's Economic Capital Ratio, given in the ranking table, is 317%, being 83% points above the market average of 234%.

Input Variable	Value in 1000 USD
Assets, Current	562,455
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	212,577
Liabilities, Non-Current	80,500
Other Assets	589,578
Other Compr. Net Income	0
Other Expenses	170,778
Other Liabilities	265,632
Other Net Income	-18,665
Other Revenues	743,183
Property and Equipment	366,046
Research and Development	180,015
Selling, General and Administrative Expense	156,482

Output Variable	Value in 1000 USD
Assets	1,518,079
Liabilities	558,709
Expenses	507,275
Revenues	743,183
Stockholders Equity	959,370
Net Income	217,243
Comprehensive Net Income	217,243
BaseVar	1,672,956
ECR before Limited Liability	222%
Economic Capital Ratio	317%